logo
Plus   Neg
Share
Email

Sandoz To Appeal U.S. Court Ruling In Biosimilar Erelzi U.S. Patent Case

Sandoz, a Novartis division (NVS), said that the United States District Court of New Jersey ruled against Sandoz in patent litigation regarding the Sandoz biosimilar, Erelzi or etanercept-szzs for reference medicine Enbrel or etanercept. The company will appeal the ruling to the U.S. Court of Appeals for the Federal Circuit, and the parties have agreed to an expedited appeal.

Sandoz said it disagreed with the Court's ruling, which prevents the company from launching an additional treatment option for patients with autoimmune and inflammatory diseases. It continues to consider the patents in this case to be invalid.

According to Sandoz, Amgen asserted two patents that it obtained from Roche, in what Sandoz believes is an attempt to extend its US compound patent protection for etanercept to 2029.oz said, "We will appeal this decision, and look forward to presenting our case to the Federal Circuit and bringing Erelzi to US patients as soon as possible."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT